Background: Development of new blood vessels is essential for tumor growth and metastasis and depends on the production of angiogenic factors by tumor and/or infiltrating cells. We previously showed that vascular endothelial growth factor (VEGF) expression and vessel count correlate with metastasis in human colon cancer. Although most tumors with high vessel counts express high levels of VEGF, some do not. Recently, platelet-derived endothelial cell growth factor (PD-ECGF), another potent angiogenic factor, has been reported to be expressed in colon cancer. Purpose: In this study, we examined the role of PD-ECGF in colon cancer angiogenesis and whether PD-ECGF is derived from the tumor or infiltrating cells. Methods: Immunostaining for PD-ECGF was performed on 96 colon cancer specimens, some of which were previously stained for VEGF and factor VIII, a marker that is specific for endothelial cells. Double staining was done by using antibodies to PD-ECGF and to CD68 (macrophage specific) or CD3 (lymphocyte specific) to confirm which infiltrating cells produce PD-ECGF. Northern blot analysis for PD-ECGF messenger RNA (mRNA) was performed on four colon cancer specimens and corresponding normal colon mucosae (same patients) and four human colon cancer cell lines
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Platelet-derived endothelial cell growth factor (PD-ECGF) is an endothelial cell mitogen initially purified to homogeneity from human platelets (8, 9) . PD-ECGF has chemotactic activity for endothelial cells in vitro and is angiogenic in vivo (9) . PD-ECGF has also been demonstrated to be identical to thymidine phosphorylase, an enzyme involved in pyrimidine nucleoside metabolism (10, 11) . PD-ECGF expression is elevated in several solid tumor types (12) (13) (14) (15) (16) (17) .
We recently demonstrated (7) that vascular endothelial growth factor (VEGF) and vessel count correlate with metastasis in human colon cancer. Although most tumors with high vessel counts expressed high levels of VEGF, some did not. It was recently reported (18) that the expression of thymidine phosphorylase is higher in colorectal carcinomas than in colorectal adenomas and normal tissues, and we hypothesized that PD-ECGF is associated with colon cancer angiogenesis.
In this study, we sought to determine whether PD-ECGF is associated with vessel count in human colon cancers and whether PD-ECGF is derived from the tumor epithelium or infiltrating cells.
Materials and Methods

Patients
Paraffin-embedded tumor specimens from % randomly chosen patients with colon cancers who had undergone surgery (1988) (1989) (1990) (1991) (1992) (1993) After an initial review of all available hematoxylin-eosin-stained slides of the surgical specimen sections, we selected one representative paraffin block from each case for further study. Blocks selected were those in which mucosa, invasive edge, and viable tumor were present. Consecutive 4-um sections were recut from each study block; these sections were immunostained for PD-ECGF, VEGF, and factor VIII. Cases were selected at random, mostly by availability of blocks, where proper staging was available, omitting any cases where preoperative therapy was given.
Immunohistochemical Staining
Many of the colon cancer specimens were previously stained for VEGF and factor VIII, and the results have been published (7) . A portion of these data was used in the present analyses. Immunohistochemical staining was performed by the immunoperoxidase technique. Paraffin sections were dewaxed in three changes of xylene followed by rinsing in graded ethanol and finally rehydrated in three changes of phosphate-buffered saline (PBS). Antigen retrieval was performed by trypsinization to unmask tissue antigens (with the exception of PD-ECGF). For PD-ECGF, microwave treatment was done to unmask the antigen, since this gave a more reproducible reaction when compared with trypsin digestion. Endogenous peroxidase was blocked by incubating the sections with 3% hydrogen peroxide in methanol for 10 minutes. After rinsing with PBS three times, nonspecific reaction was blocked by incubating the sections in a solution containing 5% normal horse serum and 1 % normal goat serum. The sections were then incubated with appropriate dilutions of the primary antibody at 4 'C overnight The antibodies used were a rabbit polyclonal immunoglobulin G (IgG) antibody (Santa Cruz Biotechnology, CA) for VEGF at a 1:200 dilution, a mouse monoclonal IgG antibody (from Y. Tanaka, Rosche Institute, Kamakura, Japan) for PD-ECGF at a 1:150 dilution, a peroxidase-conjugated rabbit anti-human polyclonal antibody (Dakopatts, Glostrup, Denmark) for factor VIH-related antigens at a 1:250 dilution, a mouse IgG monoclonal antibody (Dakopatts) for anti-CD68 (specific for macrophages) at a 1:50 dilution, and a rabbit polyclonal antibody (Dakopatts) for anti-CD3 (specific for lymphocytes) at a 1:100 dilution. For positive controls, colon cancer specimens known to express VEGF or PD-ECGF were stained for VEGF or PD-ECGF. Negative controls were done using nonspecific mouse or rabbit IgG as the primary antibody at the same IgG concentration as the test antibody (see above). After 3-5-minute rinses with PBS, the sections were incubated with the appropriate peroxidase-labeled secondary antibody for 1 hour at room temperature (PD-ECGF, VEGF, CD68, and CD3). For factor VIH-related antigen, direct immunoperoxidase staining was done without use of a secondary antibody, since the primary antibody was peroxidase conjugated. After three rinses with PBS, the sections were incubated with diaminobenzidine substrate (Research Genetics, Huntsville, AL) for 7 minutes. The sections were nnsed with distilled water and counterstained with Mayer's hematoxylin.
On representative samples, phenotyping of PD-ECGF-staining cells was performed by a doublestaining procedure, whereby the sections were stained sequentially by immunoperoxidase for PD-ECGF followed by immunoalkaline phosphatase for either CD68 or CD3. Sections were examined for the presence of cells that were stained red alone (alkaline phosphatase staining [CD68 or CD3]), brown alone (peroxidase staining [PD-ECGF]), or both red and brown (double staining). Serial sections were stained separately by either immunoperoxidase or immunoalkaline phosphatase as controls.
Evaluation of Immunostaining and Vessel Counting
For evaluation of intensity of staining, groups of cells with the strongest staining within each tumor were examined. The intensity of VEGF staining of tumor cells was graded on an arbitrary scale of 0-3+, with 0 representing no detectable stain and 3+ representing the strongest stain. The intensity of PD-ECGF staining of infiltrating cells was also graded on an arbitrary scale of 0-3+: 0 = no PD-ECGFpositive infiltrating cells; 1+ = slight staining of infiltrating cells; 2+ = moderate staining; and 3+ = strongest staining. The intensity of staining for VEGF and PD-ECGF was confirmed in tumor and infiltrating cells at the invasive edge as previously described by an image analyzer using the Optimas software program (Optimas Corp., Bothell, WA) (7).
Vessel count (factor VHI-positive cells) was assessed by light microscopy in areas of the tumor containing the highest numbers of capillaries and small venules at the invasive edge, on the basis of the criteria of Weidner et al. (3) . The highly vascular areas were identified by scanning tumor sections at low power (40x and lOOx). After the area of highest neovascularization was identified, individual vessel count was performed on a 200x field (high-power field, i.e., 20x objective and lOx ocular, 0.739 mm 2 per field). The vessel count of 50 or more per highpower field was considered high. These evaluations were done by two investigators (Y. Takahashi and Y. Kitadai) without knowledge of the patient's stage of disease with less than 10% differences between the two observers.
Northern Blot Analysis
We also assessed PD-ECGF messenger RNA (mRNA) expression in tumor cell lines, normal human colon mucosae, and colon cancer specimens. The human colon cancer cell line KM 12SM was obtained from I. J. Fidler and was grown as previously described (20) . The human colon cancer cell lines SW620, HT29, and NCI-H508 were obtained from the American Type Culture Collection (Rockville, MD) and were grown under conditions recommended by the supplier. Tumor tissues and corresponding normal mucosae (at least 10 cm from the primary rumor) from four surgical patients with colon cancer were snap frozen in liquid nitrogen after removal and stored in liquid nitrogen until processing.
Polyadenylic acid mRNA was extracted from the tumor tissues, normal mucosae, and cell lines using the Fast Track mRNA isolation kit (Invitrogen Co., San Diego, CA). mRNA was subjected to electrophoresis in a 1% agarose gel containing formaldehyde (2.2 M), and the separated species were transferred electrophoretically (0.6 A) to GeneScreen nylon membranes (Du Pont NEN, Boston, MA). The transferred mRNAs were cross-linked using a UV Stratalinker 1800 (120 000 uJ/cm 2 ) (Stratagene, La Jolla, CA). Hybridizations with complementary DNA (cDNA) probes were performed as described previously (21) . Probed membranes were washed at 65 "C with 30 mM NaCl, 3 mM sodium citrate (pH 7.2), and 0.1% sodium dodecyl sulfate (wt/vol).
The cDNA probes used in this analysis were obtained using a 1.3-kilobase (kb) Pst I restriction fragment containing rat glyceraldehyde phosphate dehydrogenase (GAPDH) cDNA sequences (22) (internal control) and a 1.8-kb EcoRl restriction fragment cDNA sequence containing PD-ECGF (from C.-H. Heldin) (9) . Each restriction fragment was purified by agarose gel electrophoresis, isolated as the templates using GeneClean (BIO, Inc., La Jolla, CA), and radiolabeled with [a-
32 P]deoxyribonucleotide triphosphate by use of the random-priming technique (23) .
Densitometric Quantitation
Expression of PD-ECGF mRNA was quantified by densitometry of autoradiograms using the Image QuantTM software program (Molecular Dynamics, Sunnyvale, CA). The value for each sample was derived by calculating the ratio of the average areas for the specific mRNA transcripts to the average area for the GAPDH mRNA transcript (internal control for loading).
Statistical Analyses
Correlations between the intensity of staining for PD-ECGF in infiltrating cells and VEGF expression, and vessel counts were examined by the Spearman's rank correlation coefficient (/?)• Differences between the intensity of staining for PD-ECGF in infiltrating cells in those patients with and without metastasis at the time of presentation were examined by the twosided Mann-Whitney U test. The difference in PD-ECGF staining intensity between specimens with high vessel counts and high VEGF-staining intensity and those with high vessel counts but low VEGF-staining intensity was analyzed by a two-sided Student's / test. Differences in vessel counts among groups were determined by use of a two-sided Student's t test. A value of PS.05 was deemed significant Statistical analyses were done using Statworks statistical software (Student's I test) (Cricket Software, Inc., Philadelphia, PA) and Statistica for the Macintosh (StatSoft Inc., Tulsa, OK).
Results
Immunohistochemical Staining for PD-ECGF
Eighty (83%) of the 96 tumors demonstrated PD-ECGF protein in infiltrating cells. In contrast, only five (5%) of the 96 tumors stained positive for PD-ECGF in tumor epithelium; the intensity of epithelial staining was very low (only 1+ in most positive-staining specimens). Table  1 demonstrates the staining intensity of PD-ECGF in cancer epithelium and infiltrating cells in nonmetastatic and metastatic tumors: there is no difference in staining intensity in either the cancer epithelium or infiltrating cells between metastatic and nonmetastatic tumors (P = .788 and P = .464, respectively).
Correlation Between the Intensity of PD-ECGF Staining and Metastasis, VEGF Expression, and Vessel Count
Representative photomicrographs of colon cancer specimens stained for factor VHI-related antigen, PD-ECGF, and infiltrating cells are shown in Fig. 1 . There was no difference in the intensity of PD-ECGF staining in infiltrating cells between patients with nonmetastatic and metastatic colon cancers (P = .464). The intensity of VEGF staining did not correlate with the intensity of PD-ECGF staining (R = .176) (P = .086). However, vessel counts strongly correlated with the intensity of PD-ECGF staining in infiltrating cells (/? = .29) (P = .004).
Double Staining for PD-ECGF and Macrophages
Most PD-ECGF-positive cells also stained positive for CD68 (specific for macrophages). As shown in Fig. 1 , E-F, many of the infiltrating cells stained positive for both PD-ECGF and CD68. However, some cells stained positive only for either PD-ECGF or CD68. In addition, cells that stained for both PD-ECGF and CD3 were also present but were less populous than PD-ECGF/CD68-staining cells. This suggests that PD-ECGF may be expressed by both macrophages and lymphocytes.
Vessel Counts (Factor VIII)
The mean vessel count per high-power field in colon cancer specimens from the entire group of 96 patients was 38 ± 17 (mean ± standard deviation). The mean vessel count in those patients who presented with metastasis (Dukes' stage C or D) was significantly higher than in those patients who presented with a lessor stage of disease (Dukes' stage A or B) (47 versus 31, f<.001). In patients with high PD-ECGF expression in the infiltrating cells (3+), the mean vessel count was significantly greater than in those tumors with lower PD-ECGF expression (46 versus 36, respectively, P -.030).
PD-ECGF-Staining Intensity in Specimens With High Vessel Count and Low VEGF Expression
A previous study (7) demonstrated that some tumors with high vessel counts expressed low levels of VEGF. Therefore, to determine whether PD-ECGF was associated with vascularity in this group of tumors, we compared the intensity of PD-ECGF staining in infiltrating cells in the specimens with vessel counts higher than 50 per high-power field (higher than the mean value) but VEGF staining intensity of 2+ or less and in the specimens with vessel counts higher than 50 and VEGF staining intensity of 3+. The mean intensity of PD-ECGF staining in infiltrating cells in patients with high vessel count/low VEGF was significantly higher than in the high vessel count/high VEGF (P = .011) ( Table 2) .
Northern Blot Analysis for PD-ECGF Expression
Colon cancers and corresponding normal mucosae from four patients expressed relatively high levels of PD-ECGF mRNA, whereas PD-ECGF was not detected in the colon cancer cell lines by northern blot analysis (Fig. 2) . There was no difference in the level of PD-ECGF mRNA between normal mucosae and colon cancer.
Discussion
The process of angiogenesis is the outcome of an imbalance between positive and negative regulators of neovascularization. Since the initial discovery by Folkman (1,2) that tumors are angiogenesis dependent, a myriad of positive and negative regulators of angiogenesis has been discovered. Although many factors may induce angiogenesis in vivo (9), not all induce endothelial cell proliferation in vitro. Thus, it is possible that some angiogenic factors act through a second messenger system either by inducing the expression of other angiogenic factors or by contributing to the angiogenic response through some type of enzymatic activity.
PD-ECGF has been demonstrated to induce chemotaxis of endothelial cells and angiogenesis in vivo, but it does not stimulate the growth of endothelial cells in vitro (9) . The amino acid sequence for PD-ECGF does not contain a signal peptide, and PD-ECGF is not a classic paracrine growth factor in this regard. In fact, the amino acid sequence for PD-ECGF has been found to be identical to that of thymidine phosphorylase. The enzymatic activity of this thymidine phosphorylase is necessary for the angiogenic response (24) .
Because of the complex nature of the angiogenic process, it is unlikely that any Table 1 . Expression of platelet-derived endothelial cell growth factor protein in colon cancer epithelium and infiltrating cells one factor is responsible for angiogenesis in a particular tumor type. Within any individual tumor, there may be a dominant angiogenic factor that favors the imbalance of the positive and negative regulators to induce angiogenesis. In previous studies from our laboratory (7), we noted a correlation between VEGF expression and vessel count in human colon cancers. However, we also noted that several tumors exhibited a very high vessel count but had relatively low levels of VEGF. To determine whether another angiogenic factor is responsible for this increase in angiogenic activity, we investigated the role of PD-ECGF in human colon cancer angiogenesis. With the use of immunohistochemical techniques, we found that the colon cancer epithelium rarely stained for this factor, instead, most staining was in the infiltrating cells. ECGF and VEGF are redundant, additive, or synergistic remains to be determined. Antiangiogenic therapy is currently being explored both in the laboratory and in the clinic. It is possible that we will need to determine the "angiogenic phenotype" of individual tumors to provide the proper antiangiogenic therapy (57). Determining the angiogenic factors necessary to induce angiogenesis will allow the development of agents to alter expression of such factors. In addition, determining the cell of origin of these angiogenic factors will allow antiangiogenic agents to be targeted to those cells. It is possible that PD-ECGF may be used as a target for antiangiogenic therapy in the future.
interesting was the fact that in specimens with a high vessel count but low VEGF expression, we found an increase in the expression of PD-ECGF in the infiltrating cells. To determine the cell of origin of PD-ECGF in the interstitium, we stained colon cancer specimens with markers specific for macrophages and lymphocytes. These immune cells are known to express other angiogenic factors, including basic fibroblast growth factor (25), transforming growth factor-a (26), platelet-derived growth factor (27) , VEGF (28) , and interleukin 8 (29) . The observation that infiltrating cells may contribute to the angiogenic response in solid cancers was initially made by Polverini and Leibovich (30) in both in vivo and in vitro systems. These investigators demonstrated that tumor-associated macrophages and their conditioned media induce neovascularization in the comea. This study also suggested that tumorassociated macrophages may induce a stronger angiogenic response than peritoneal macrophages. Conditioned media from tumor-associated, macrophages induced a 10-fold increase in endothelial cell proliferation (30) . There are no reports in the literature of infiltrating immune cells expressing PD-ECGF. By the double-staining technique, we were able to demonstrate that PD-ECGF is expressed by infiltrating cells in human colon cancers. We noted very weak staining of the tumor epithelium itself, and similar findings were noted by Takebayashi et al. (18) . To confirm that the epithelium makes very little, if any, PD-ECGF, we performed northern blot analysis on human colon cancer specimens, normal colon mucosae from patients with colon cancer, and colon cancer cell lines. If specimens from patients exhibit PD-ECGF but epithelial cell lines grown in vitro do not, then it is likely that a cell other than the tumor epithelium synthesizes PD-ECGF. By the use of northern blot analysis, we found PD-ECGF present in both the mucosae and tumors, but we did not detect PD-ECGF in a pure population of human colon cancer cells grown in vitro. Normal mucosae and colon cancers are infiltrated by numerous immune cells, and we believe that any effect of PD-ECGF on angiogenesis in human colon cancers is through the infiltrating cells. The effect of PD-ECGF on angiogenesis may not be direct but may be through another angiogenic factor or through facilitating endothelial cell invasion through its enzymatic activity. The exact mechanism by which PD-ECGF induces tumor angiogenesis is unknown at present.
Other investigators have examined the role of PD-ECGF in solid cancers. Takebayashi et al. (18) examined PD-ECGF expression in patients with colon cancer and showed increased expression in colon cancer compared with adenomas or normal mucosa. O'Brien et al. (16) demonstrated that PD-ECGF may be important in invasive bladder cancer, whereas VEGF is more commonly found in the papillary type of bladder cancer. Toi et al. (17) demonstrated that PD-ECGF and VEGF are frequently coexpressed in highly vascularized human breast cancer specimens. Whether PD-
